WO2023046304A1 - [6r]-mthf dans une chimiothérapie à base de 5-fu de cancer colorectal à mutation de kras ou braf - Google Patents
[6r]-mthf dans une chimiothérapie à base de 5-fu de cancer colorectal à mutation de kras ou braf Download PDFInfo
- Publication number
- WO2023046304A1 WO2023046304A1 PCT/EP2021/076512 EP2021076512W WO2023046304A1 WO 2023046304 A1 WO2023046304 A1 WO 2023046304A1 EP 2021076512 W EP2021076512 W EP 2021076512W WO 2023046304 A1 WO2023046304 A1 WO 2023046304A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- patient
- colorectal cancer
- positive
- braf
- Prior art date
Links
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 97
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 97
- 238000002512 chemotherapy Methods 0.000 title abstract description 6
- 238000011282 treatment Methods 0.000 claims abstract description 145
- QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 claims abstract description 84
- 206010069755 K-ras gene mutation Diseases 0.000 claims abstract description 43
- 229960002949 fluorouracil Drugs 0.000 claims abstract description 40
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims abstract description 39
- 206010028980 Neoplasm Diseases 0.000 claims description 116
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 83
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 83
- 238000012360 testing method Methods 0.000 claims description 64
- 230000035772 mutation Effects 0.000 claims description 59
- 239000007787 solid Substances 0.000 claims description 32
- 229960000397 bevacizumab Drugs 0.000 claims description 25
- 238000004458 analytical method Methods 0.000 claims description 19
- 229960001756 oxaliplatin Drugs 0.000 claims description 16
- 238000001802 infusion Methods 0.000 claims description 15
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 14
- 238000001990 intravenous administration Methods 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- 229960004768 irinotecan Drugs 0.000 claims description 11
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 11
- 230000002411 adverse Effects 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 230000000977 initiatory effect Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 5
- 206010061818 Disease progression Diseases 0.000 claims description 5
- 230000005750 disease progression Effects 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 claims description 4
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims description 4
- 229960001674 tegafur Drugs 0.000 claims description 4
- 238000011528 liquid biopsy Methods 0.000 claims description 3
- HPABFFGQPLJKBP-UHFFFAOYSA-N 5-fluoro-1H-pyrimidin-2-one Chemical compound OC1=NC=C(F)C=N1 HPABFFGQPLJKBP-UHFFFAOYSA-N 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- -1 UFT Chemical compound 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229950005454 doxifluridine Drugs 0.000 claims description 2
- 238000011304 droplet digital PCR Methods 0.000 claims description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- WTSKMKRYHATLLL-UHFFFAOYSA-N (6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate Chemical compound O=C1N(COCC)C=C(F)C(=O)N1C(=O)C1=CC=CC(C(=O)OC=2C(=CC=C(OC(=O)C=3C=CC=CC=3)N=2)C#N)=C1 WTSKMKRYHATLLL-UHFFFAOYSA-N 0.000 claims 1
- 230000003902 lesion Effects 0.000 description 99
- 102100030708 GTPase KRas Human genes 0.000 description 55
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 55
- 230000004044 response Effects 0.000 description 50
- 230000003247 decreasing effect Effects 0.000 description 34
- 230000036961 partial effect Effects 0.000 description 32
- 238000009098 adjuvant therapy Methods 0.000 description 31
- 201000010099 disease Diseases 0.000 description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 102100039788 GTPase NRas Human genes 0.000 description 24
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 24
- 210000004185 liver Anatomy 0.000 description 22
- 229950009553 arfolitixorin Drugs 0.000 description 21
- 229940124301 concurrent medication Drugs 0.000 description 21
- 208000037821 progressive disease Diseases 0.000 description 14
- 206010027476 Metastases Diseases 0.000 description 13
- 239000011672 folinic acid Substances 0.000 description 13
- 229960001691 leucovorin Drugs 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 13
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 12
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 12
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 11
- 235000008191 folinic acid Nutrition 0.000 description 11
- 230000009401 metastasis Effects 0.000 description 11
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 8
- 206010028813 Nausea Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000008693 nausea Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 description 7
- 239000000090 biomarker Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 206010016256 fatigue Diseases 0.000 description 6
- 229940014144 folate Drugs 0.000 description 6
- 235000019152 folic acid Nutrition 0.000 description 6
- 239000011724 folic acid Substances 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000016914 ras Proteins Human genes 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 description 4
- 102100028843 DNA mismatch repair protein Mlh1 Human genes 0.000 description 4
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 description 4
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 229910015837 MSH2 Inorganic materials 0.000 description 4
- 208000032818 Microsatellite Instability Diseases 0.000 description 4
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 description 4
- 102100037480 Mismatch repair endonuclease PMS2 Human genes 0.000 description 4
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 description 4
- 229940008678 levoleucovorin Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 206010003658 Atrial Fibrillation Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 description 3
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 102000049937 Smad4 Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 238000010197 meta-analysis Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 2
- PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010018498 Goitre Diseases 0.000 description 2
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 2
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 2
- 101150105104 Kras gene Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 206010027457 Metastases to liver Diseases 0.000 description 2
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 208000005793 Restless legs syndrome Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012321 colectomy Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000007453 hemicolectomy Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 208000004235 neutropenia Diseases 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000004197 pelvis Anatomy 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940035073 symbicort Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000007395 thrombosis prophylaxis Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- TZBGSHAFWLGWBO-ABLWVSNPSA-N (2s)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pteridin-6-yl)methylamino]benzoyl]amino]-5-methoxy-5-oxopentanoic acid Chemical group C1=CC(C(=O)N[C@@H](CCC(=O)OC)C(O)=O)=CC=C1NCC1NC(C(=O)NC(N)=N2)=C2NC1 TZBGSHAFWLGWBO-ABLWVSNPSA-N 0.000 description 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
- QYNUQALWYRSVHF-ABLWVSNPSA-N 5,10-methylenetetrahydrofolic acid Chemical compound C1N2C=3C(=O)NC(N)=NC=3NCC2CN1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-ABLWVSNPSA-N 0.000 description 1
- HFEKDTCAMMOLQP-RRKCRQDMSA-N 5-fluorodeoxyuridine monophosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 HFEKDTCAMMOLQP-RRKCRQDMSA-N 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 241001156002 Anthonomus pomorum Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 206010009126 Chronic respiratory failure Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010055114 Colon cancer metastatic Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000002633 Febrile Neutropenia Diseases 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010056342 Pulmonary mass Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 206010003668 atrial tachycardia Diseases 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 101150048834 braF gene Proteins 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 238000011354 first-line chemotherapy Methods 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 210000005161 hepatic lobe Anatomy 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 238000007455 ileostomy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- CRC Colorectal cancer
- CRC is not a single type of tumor; its pathogenesis depends on the anatomical location of the tumor and differs between right side and left side of the colon. Further, CRC is a multigenetic disease, as several oncogenes are involved frequently in this process. Oncogenic mutations spread differently, based on specific anatomical regions.
- Huang and coworkers identified six key driver genes, namely APC, KRAS, BRAF, PIK3CA, SMAD4 and p53. Through a systematic search, 120 articles published by November 30, 2017 were included, which all showed roles for these gene mutations in CRC metastasis. A meta-analysis showed that KRAS mutations (combined OR 1.18, 95% Cl 1.05-1.33) and p53 mutations (combined OR 1.49, 95% Cl 1.23-1.80) were associated with CRC metastasis, including lymphatic and distant metastases.
- CRC patients with a KRAS mutation (combined OR 1.29, 95% Cl 1.13-1.47), p53 mutation (combined OR 1.35, 95% Cl 1.06-1.72) or SMAD4 mutation (combined OR 2.04, 95%CI 1.41- 2.95) were at a higher risk of distant metastasis.
- BRAF and KRAS both belong to a class of genes known as oncogenes. When mutated, oncogenes have the potential to cause normal cells to become cancerous.
- B-Raf is a protein encoded by the BRAF gene and is involved in the RAS/MAPK pathway, which regulates cellular growth and division.
- BRAF mutations are found in 8-12% of cases of mCRC, with the predominance of BRAF V600E in approximately 90% of BRAF-mutant CRC.
- BRAF V600E is a point mutation at nucleotide 1799 that results in independent activation of its upstream activator protein, RAS, as well as increased stimulation of its downstream effector proteins, MEK and ERK, via phosphorylation.
- RAS and BRAF mutations are usually mutually exclusive (Tabernero 2020).
- the KRAS gene encodes for a protein called K-Ras that is also part of the RAS/MAPK pathway.
- KRAS mutation rates are different among CRC patients belonging to different ethnicities. In Caucasians, the frequency of CRC with KRAS mutations is equal to 38%; in Asians, it is close to 40%; and, in Africans, it is only 21%. Most KRAS mutations in CRC occur within KRAS exon 2, with prevalence ranging from 10% to 47%, typically in codons 12 and 13. In addition, approximately 10% of patients with CRC are characterized by other types of KRAS mutations. Mutations in the KRAS gene are detected in approximately 25% of all human cancers; rates are highest in pancreatic carcinoma, reaching above 80%, while, in CRC, they are found in about 40% of cases (Cefali 2021).
- the KRAS mutation has been found to have an adverse impact on the prognosis for stage IV CRC patients treated with the FOLFOX regimen (Zocche 2015) or on stage II or III CRC patients treated with adjuvant FOLFOX (Lee 2014).
- FOLFOX regimen Zocche 2015
- stage II or III CRC patients treated with adjuvant FOLFOX Lee 2014
- FOLFOX adjuvant FOLFOX
- ORR best overall response
- KRAS mutations have further been found to confer resistance to epidermal growth factor receptor (EGFR) inhibitors, a class of tyrosine kinase inhibitors or monoclonal antibodies designed to slow or halt uncontrolled cell growth (Bai 2015).
- EGFR epidermal growth factor receptor
- CRC patients with BRAF-mutations do not benefit, either, from EGFR inhibitors.
- the current standard therapy in first-line treatment of BRAF-mutated CRC is folate/5-fluorouracil (5-FU) assisted oxaliplatin-based chemotherapy plus bevacizumab, increasingly including the more intensive "triplet" therapy FOLFOXIRI (/.e. leucovorin/5-FU/oxaliplatin/ irinotecan) plus bevacizumab, which however is only a valid option in patients with a good ECOG (Eastern Cooperative Oncology Group) performance status (Caputo 2019).
- Triplet chemotherapy has thus been found to be a very good option for otherwise fit CRC patients with aggressive tumors, and has also been suggested for KRAS-mutated CRC cases (Glynne-Jones 2020).
- FOLFOXIRI plus bevacizumab triplet therapy is in general associated with a highly increased level of adverse side effects.
- FOLFOX or FOLFIRI patients in the triplet group
- FOLFOXIRI plus bevacizumab triplet therapy therefore remains recommended only for patients whose general condition is very good, estimated to around 40-50% of all mCRC patients; discounting the elderly (Cremolini 2019).
- Leucovorin® orfolinic acid shall both mean 5-formyl tetrahydrofolic acid, i.e. the 5-formyl derivative of tetrahydrofolic acid.
- Folinic acid contains 2 asymmetric centers.
- Commercially available leucovorin (LV) is composed of a 1:1 mixture of the dextrorotary and levo- rotary diastereomers (d-leucovorin (d-LV, (6R,2'S)-configuration) and /-leucovorin (/-LV, (6S,2'S)- configuration), respectively), and may also be referred to as (d,/-LV).
- Levoleucovorin shall refer to the commercially available product which contains only the pharmacologically active /evo-isomer /-LV (or LLV). In vitro, /-LV has been shown to be rapidly converted to the biologically available methyl-tetrahydrofolate form while the dextro form c/-LV (DLV) is slowly excreted by the kidneys. Leucovorin and levoleucovorin have however been shown to be pharmacokinetically identical and may be used interchangeably with limited differences in efficacy or side effects (Kovoor et al, Clin Colorectal Cancer 8 200-6 (2009).
- MTHF or methyleneTHF shall both refer to 5,10-Methylene-5,6,7,8- tetrahydrofolate.
- racemic methyleneTHF, CoFactor® or [6R,S]-5,10-methyleneTHF shall all refer to the 1:1 diastereomeric mixture [6R,S]-5,10-Methylene-5,6,7,8-tetrahydrofolate.
- [6R]-5,10-MTHF shall refer to the single diastereomer, [6R]-5,10- methylenetetrahydrofolate.
- IV or i.v. shall both mean intravenous.
- best ORR shall refer to the best overall response rate as per RECIST guideline version 1.1 for the treatment period, where applicable.
- BSA Body Surface Area
- CRC refers to colorectal cancer.
- mCRC shall refer to metastatic colorectal cancer.
- BRAF mutation-positive patients and KRAS mutation-positive patients shall refer to patients who by genotype testing have been found to harbor either BRAF- or KRAS mutated tumors and/or metastases.
- ctDNA genotype testing shall refer to genotype testing conducted by analyzing a blood or serum sample for cell-free tumor DNA.
- Arfolitixorin (Modufolin®) is a new drug developed to increase the efficacy of the cytotoxic agent 5-fluorouracil (5-FU) and as a rescue drug after high-dose methotrexate treatment.
- Arfolitixorin (Modufolin®) [6R]-5,10-methylenetetrahydrofolate, abbreviated herein as [6R]- 5,10-MTHF, needs to be metabolically formed when using the widely used folate-based drugs leucovorin and levoleucovorin.
- Arfolitixorin (Modufolin®) does not require metabolic activation to exert its effect and may therefore be suitable for all patients.
- patients diagnosed with colorectal cancer and further determined by genotype testing to be either BRAF mutation-positive or KRAS mutation-positive or both BRAF mutation-positive and KRAS mutation-positive, i.e. harboring BRAF mutation- and/or KRAS mutation-positive colorectal cancer tumors may be treated according to a chemotherapeutic protocol over at least 16 weeks involving i.a. administration of multiple, rapid boluses of [6R]-5,10-MTHF, by which treatment best ORRs (objective response rates) of >50% can be achieved.
- [6R]-5,10-methylenetetrahydrofolate for use in a human patient in the treatment of solid colorectal cancer tumors, which treatment comprises the following steps: a) administering a continuous IV infusion containing 85 mg/m 2 (of BSA) oxaliplatin, followed by b) administering an IV bolus containing 400 mg/m 2 (of BSA) 5-fluorouracil, followed by c) administering an IV bolus containing 60 mg/m 2 [6R]-5,10-methylenetetrahydro- folate, followed by d) administering a continuous IV infusion containing 2400 mg/m 2 5-fluorouracil over 46 hours ⁇ 1 hour followed by e) administering an IV bolus containing 60 mg/m 2 (of BSA) [6R]-5,10-methylenetet- rahydrofolate, wherein said human patient has been found by genotype testing to be either BRAF mutation
- [6R]-5,10-methylenetetrahydrofolate for use in a human patient in the treatment of solid colorectal cancer tumors, which treatment comprises the following steps: a) administering a continuous IV infusion containing 180 mg/m 2 (of BSA) irinotecan, followed by b) administering an IV bolus containing 400 mg/m 2 (of BSA) 5-fluorouracil, followed by c) administering an IV bolus containing 60 mg/m 2 [6R]-5,10-methylenetetrahydro- folate, followed by d) administering a continuous IV infusion containing 2400 mg/m 2 5-fluorouracil over 46 hours ⁇ 1 hour followed by e) administering an IV bolus containing 60 mg/m 2 (of BSA) [6R]-5,10-methylenetetra- hydrofolate, wherein said human patient has been found by genotype testing to be either BRAF mutationpositive or KRAS mutation
- the treatment based on the ARFOX or ARFIRI protocol may in principle be terminated "for any reason", such as e.g. by a patient decision or a decision taken by the responsible medical person, i.a. due to disease progression or adverse events. Furthermore, the ARFOX or ARFIRI protocol may be interrupted by treatment holidays and the like. Finally the responsible medical person may decide on a fixed number of treatment cycles.
- [6R]-5,10-methylene-tetrahydrofolate is therefore provided for use in the retardation or prevention of the progression in a human patient of solid colorectal cancer tumors, wherein said human patient has been found by genotype testing to be either BRAF mutation-positive or KRAS mutation-positive or both BRAF mutation-positive and KRAS mutation-positive, which comprises performing and repeating steps a) to e) according to the first or second aspect of the present invention, over a total treatment period of at least 16 weeks.
- a method for retardation or prevention of the progression in a human of solid colorectal cancer tumors wherein said human patient has been found by genotype testing to be either BRAF mutation-positive or KRAS mutation-positive or both BRAF mutation-positive and KRAS mutation-positive, which method comprises performing and repeating steps a) to e) according to the first or second aspect of the present invention, over a total treatment period of at least 16 weeks.
- DESCRIPTION OF FIGURES Figure 1 (adapted from Huang 2018): Table showing a subgroup analysis for the association between KRAS, BRAF and p53 mutations and CRC distant metastasis
- Figure 2 is a table of all the 31 participating patients in the follow-up study including a status for each patient as regards KRAS and BRAF genotype results.
- Arfolitixorin has been in development for a number of years and has been studied in several clinical studies. During one of these studies (the Phase l/lla study ISO-CC-005) it was surprisingly discovered in December 2017 that administration of [6R]-MTHF and 5-FU according to a particular treatment regimen over a treatment period of at least 8 weeks lead to a prevention or retarding of the progression in a human of solid tumors. No statistically significant progression of said solid tumors was observed between 8 and 16 weeks after initiating treatment. These results are discussed i.a. in applicant's international patent application WO 2019/037899 published 28 February 2019. The completion of the study was announced in January 2020. In total, 105 patients were included in the study.
- Applicant completed the dose definition part of ISO-CC-005 in March 2018, which evaluated the safety and efficacy of arfolitixorin in patients with mCRC. Shortly after, applicant started two additional treatment groups in 2018 to generate more safety and efficacy data, i.e. the safety extension Cohort #18 (Treatment Arm #4) and Cohort #19 (Treatment Arm #6). The aim was to evaluate as many patients as possible from the additional treatment groups after a treatment period of 16 weeks+.
- This "mutation group” would be expected to have an overall best ORR reflecting the proportion of BRAF mutation-positive CRC patients + the proportion of KRAS mutation-positive CRC patients, which can be calculated as follows:
- the ARFIRI/ARFOX treatment protocols have proven surprisingly effective in the treatment of CRC patients having tested BRAF- or KRAS mutation-positive, and much more effective than the FOLFIRI/FOLFOX treatment protocols which employ leucovorin.
- [6R]-5,10-methylenetetrahydrofolate for use in a human patient in the treatment of solid colorectal cancer tumors, which treatment comprises the following steps: a) administering a continuous IV infusion containing 85 mg/m 2 (of BSA) oxaliplatin, followed by b) administering an IV bolus containing 400 mg/m 2 (of BSA) 5-fluorouracil, followed by c) administering an IV bolus containing 60 mg/m 2 [6R]-5,10-methylenetetrahydrofolate, followed by d) administering a continuous IV infusion containing 2400 mg/m 2 5-fluorouracil over 46 hours ⁇ 1 hour by e) administering an IV bolus containing 60 mg/m 2 (of BSA) [6R]-5,10-methylenetetrahy- drofolate, wherein said human patient has been found by genotype testing to be either BRAF mutationpositive
- [6R]-5,10-methylenetetrahydrofolate for use in a human patient in the treatment of solid colorectal cancer tumors, which treatment comprises the following steps: a) administering a continuous IV infusion containing 180 mg/m 2 (of BSA) irinotecan, followed by b) administering an IV bolus containing 400 mg/m 2 (of BSA) 5-fluorouracil, followed by c) administering an IV bolus containing 60 mg/m 2 [6R]-5,10-methylenetetrahydro- folate, followed by d) administering a continuous IV infusion containing 2400 mg/m 2 5-fluorouracil over 46 hours ⁇ 1 hour followed by e) administering an IV bolus containing 60 mg/m 2 (of BSA) [6R]-5,10-methylenetetra- hydrofolate, wherein said human patient has been found by genotype testing to be either BRAF mutationpositive or KRAS mutation
- the treatment regimen according to the first aspect is referred to as the "ARFOX” protocol
- the treatment regimen according to the second aspect is referred to as the "ARFIRI” protocol.
- the treatment based on the ARFOX or ARFIRI protocol may in principle be terminated "for any reason", such as e.g. by a patient decision or a decision taken by the responsible medical person, i.a. due to disease progression or adverse events. Furthermore, the ARFOX or ARFIRI protocol may be interrupted by treatment holidays and the like. Finally, the responsible medical person may decide on a fixed number of treatment cycles.
- ctDNA cell-free tumor DNA
- the method is also referred to as "Liquid Biopsy" analysis.
- Cell-free DNA (cfDNA) is fragmented DNA that is found in the non-cellular blood components.
- ctDNA is 150-200 base pair fragments that are released by tumor cells into the bloodstream and represents a small fraction of the total cfDNA.
- ctDNA retains epigenetic characteristics and carries tumor-specific mutations that can be detected in peripheral blood (Bi 2020). Analysis of ctDNA in plasma is based on sequencing assays, see eg Finkle 2021.
- [6R]-5,10-methylene-tetrahydrofolate is provided for use in a human patient in the treatment of solid colorectal cancer tumors, which treatment comprises steps a) - e) according to the first or second aspect of the invention, wherein the human patient has been found either by traditional tumor tissue analysis or in preferred embodiments by ctDNA analysis to be either BRAF mutation-positive or KRAS mutation-positive or both BRAF mutation-positive and KRAS mutation-positive.
- bevacizumab is administered to a human patient during the treatment period according to the first or second aspect.
- bevacizumab is administered to a human patient at a dose of 5 mg/kg as an IV infusion every two weeks.
- bevacizumab administration is initiated 8 weeks after initiating treatment.
- [6R]-5,10-methylene-tetrahydrofolate is therefore provided for use in the retardation or prevention of the progression in a human patient of solid colorectal cancer tumors, wherein said human patient has been found by genotype testing to be either BRAF mutation-positive or KRAS mutation-positive or both BRAF mutation-positive and KRAS mutation-positive, which comprises performing and repeating steps a) to e) according to the first or second aspect of the present invention, over a total treatment period of at least 16 weeks.
- [6R]-5,10-methylene- tetrahydrofolate for use in the retardation or prevention of the progression of the progression in a human of solid colorectal cancer tumors, wherein said human patient has been found by genotype testing to be either BRAF mutation-positive or KRAS mutation-positive or both BRAF mutation-positive and KRAS mutation-positive, whereby steps a) to e) according to the first or second aspect of the present invention are performed and repeated over a total treatment period of at least 16 weeks, and whereby no statistically significant progression of said solid tumors is observed between 8 and 16 weeks after initiating treatment.
- a method for retardation or prevention of the progression in a human of solid colorectal cancer tumors wherein said human patient has been found by genotype testing to be either BRAF mutation-positive or KRAS mutation-positive or both BRAF mutation-positive and KRAS mutation-positive, which method comprises performing and repeating steps a) to e) according to the first or second aspect of the present invention, over a total treatment period of at least 16 weeks.
- a method for retardation or prevention of the progression in a human of solid colorectal cancer tumors wherein said human patient has been found by genotype testing to be either BRAF mutation-positive or KRAS mutation-positive or both BRAF mutation-positive and KRAS mutation-positive, which method comprises performing and repeating steps a) to e) according to the first or second aspect of the present invention, over a total treatment period of at least 16 weeks, whereby no statistically significant progression of said solid tumors is observed between 8 and 16 weeks after initiating treatment.
- 5-fluorouracil is replaced by a fluorinated pyrimidine base such as capecitabine (Xeloda), ie. N4-pentyloxycarbonyl-5'- deoxy-5-fluorocytidine, tegafur, 5-fluoro-pyrimidinone, UFT, doxifluridine, 2'-deoxy-5 fluorouridine, 5'-deoxy-5-fluorouridine, l-(2'-oxopropyl)-5-FU, and alkyl-carbonyl-5-FU, BOF- A2, ftorafur(TS-l), and S-l.
- Xeloda capecitabine
- [6R]-5,10-methylenetetra- hydrofolate ([6R]-MTHF) is employed as a solid form which is soluble in water, such as a lyophilizate or a salt, optionally stabilized by one or more suitable excipients and/or antioxidants such as citric acid or ascorbic acid or salt forms thereof.
- the lyophilisate of 6R-MTHF is reconstituted in aqueous media.
- the lyophilisate of 6R-MTHF is prepared from 6R-MTHF hemisulfate salt. In other preferred embodiments of any of the aspects of the invention the lyophilisate is prepared from 6R-MTHF hemisulfate salt and trisodium citrate dihydrate.
- the intravenous bolus administration of steps (b), (c) and (e) occur over of a period of 10 minutes or less. In preferred embodiments of any of the aspects of the invention, the intravenous bolus administration of steps (b), (c) and (e) occur over of a period of 5 minutes or less.
- the intravenous bolus administration of steps (b), (c) and (e) occur over of a period of 3 minutes or less.
- step (c) follows step (b) after a period of 30 minutes ⁇ 5 minutes.
- step (d) follows step (c) after a period of less than 60 minutes.
- step (d) follows step (c) after a period of between 30 and 60 minutes.
- Arfolitixorin (former Modufolin®) is a folate-based biomodulator developed by applicant to improve the outcome of a range of antimetabolite treatments used within oncology.
- One of the therapeutic areas of specific interest included in the development program of Arfolitixorin is as biomodulator of 5-fluorouracil (5-FU) activity in standard treatment regime for advanced, metastatic CRC, such as Stage IV.
- Arfolitixorin The drug substance in Arfolitixorin is [6R]-5,10-MTHF described hereinabove, which is a stable formulation of the naturally occurring diastereoisomer of MTHF.
- Arfolitixorin (Modufolin®), [6R]-5,10- methylenetetrahydrofolate, abbreviated herein as [6R]-5,10-MTHF, needs to be metabolically formed when using the widely used folate-based drugs leucovorin and levoleucovorin.
- Arfolitixorin (Modufolin®) does not require metabolic activation to exert its effect and may be directly involved in the formation of the FdUMP TS ternary complex discussed hereinabove.
- Clinical Study ISO-CC-005 was an exploratory, Phase l/l I multiple-centre study to be carried out in Stadium IV CRC patients. The study was designed to show clinical relevance for patients by characterizing the tolerability of four Arfolitixorin dose levels (30, 60, 120, and 240 mg/m 2 ) in six different standard clinical settings in the presence of fixed doses of 5-FU alone or in combination with either Oxaliplatin, Irinotecan, or Oxaliplatin and Bevacizumab.
- Clinical Study ISO-CC-005 was an exploratory, Phase l/ll multiple-centre study to be carried out in Stadium IV CRC patients.
- the study was designed to show clinical relevance for patients by characterizing the tolerability of four arfolitixorin dose levels (30, 60, 120, and 240 mg/m 2 ) in six different standard clinical settings in the presence of fixed doses of 5-FU alone or in combination with either oxaliplatin, irinotecan, or oxaliplatin and bevacizumab.
- the below Table shows the initial treatment protocol for the Chemotherapy Agents (Bevacizumab, Oxaliplatin, Irinotecan, and/or 5-FU) and of the Study Drug arfolitixorin (Modufolin®): Table 1
- N/A not applicable
- SP2D selected phase 2 dose
- the time-point window for Irinotecan administration will be expanded to allow infusion times of up to 90 minutes, if necessary.
- the administered bolus 5-FU dose should not surpass the maximum recommended daily dose of 1000 mg, regardless of the body surface area.
- the tolerability of Arfolitixorin was to be determined by the presence of Dose Limiting Toxicity (DLT) in each of the treatment arms and for each investigated Arfolitixorin dose.
- DLT Dose Limiting Toxicity
- the study was divided in the Main Study and the Follow-up study.
- In the Main Study patients received study treatment with Arfolitixorin during eight (8) weeks. Patients eligible for the Follow-up study could participate until reaching progress, but no longer than 18 months.
- the Main Study was divided into a dose-finding and a proof-of-concept part.
- the goal with the Dose-finding Part of the Main Study was to establish the Arfolitixorin dose level assessed as having the most favourable profile, i.e. the selected phase 2 dose (SP2D).
- the goal with the Proof-of-concept Part of the Main Study was to acquire data on the safety and tolerability of Arfolitixorin at the SP2D dose level in settings equivalent to the two well-established combination therapies FOLFOX (i.e. Oxaliplatin/5-FU/LV) and FOLFIRI (i.e. lrinotecan/5- FU/LV).
- tumour biomarker (TK1) To evaluate the change in tumour biomarker (TK1) levels in blood after every four (4) consecutive cycles of treatment with combination therapy in the subset of patients with available blood samples.
- the patient is a 32-year-old white female randomized for treatment according to the ARFOX protocol (see above).
- Genotype testing [2018-05-10] shows patient is KRAS mutant and BRAF wildtype, NRAS wildtype.
- MSI microsatelite instability
- Baseline CT [2018-04-30] showed 1 target lesion in the liver (right lobe).
- the patient is a 64-year-old white female randomized for treatment according to the ARFOX protocol (see above).
- the primary right sided tumour is still in place and no adjuvant therapy has been given.
- Genotype testing [2018-07-27] shows patient is KRAS, BRAF and NRAS wildtype.
- Baseline CT [2018-07-02] showed 2 target lesions in the liver parenchyma.
- the patient is a 69-year-old white female randomized for treatment according to the ARFOX protocol (see above).
- the primary right sided tumour is still in place and no adjuvant therapy has been given.
- Genotype testing [2018-09-13] shows patient is KRAS wildtype, BRAF mutant, NRAS wildtype.
- Genotype testing [2019-02-14] shows patient is MMR stable.
- the primary right sided tumour has been removed and adjuvant therapy with CAPECITABINE has been given.
- Genotype testing [2018-09-13] shows patient is KRAS mutant and BRAF and NRAS wildtype.
- Baseline CT [2018-08-01] showed 1 target lesion in the left lower lobe of the lung.
- the patient is a 69-year-old white female randomized for treatment according to the ARFOX protocol (see above).
- the primary left sided tumour has been removed but no adjuvant therapy has been given.
- Genotype testing [2018-09-13] shows patient is KRAS mutant and BRAF and NRAS wildtype.
- the patient is a 71-year-old white male randomized for treatment according to the ARFOX protocol (see above).
- the primary rectal tumour is still in place and no adjuvant therapy has been given.
- Genotype testing [2018-08-24] shows patient is KRAS mutant and MLH1, PMS2 and MSH2 stable.
- Baseline CT [2018-09-14] showed 1 target lesion in the segment 6/7 of the liver.
- the patient is a 75-year-old white male randomized for treatment according to the ARFOX protocol (see above).
- Genotype testing [2018-11-06] shows patient is KRAS, BRAF and NRAS wildtype.
- Baseline CT [2018-10-12] showed 3 target lesions; 2 in the lung (left and right lower lobe) and 1 in the liver (left lobe).
- the patient is a 62-year-old white male randomized for treatment according to the ARFOX protocol (see above).
- the only medical history finding at enrolment is right colectomy and no concomitant medication.
- Genotype testing [2018-10-16] shows patient is KRAS wildtype, BRAF mutant, NRAS wildtype.
- Genotype testing [2018-10-24] shows patient is MSI negative.
- Baseline CT [2018-10-17] showed 5 target lesions in the liver, lung and tumour deposit.
- Bevacizumab treatment was initiated during the follow-up study.
- the patient is a 61-year-old white female randomized for treatment according to the ARFOX protocol (see above). Medical history findings at enrolment are hyperuricemia and hypertension that are both treated.
- the primary left sided tumour has been removed but no adjuvant therapy has been given.
- Genotype testing [2018-10-17] shows patient is KRAS wildtype, BRAF mutant, NRAS wildtype and MSI negative.
- Baseline CT [2018-10-25] showed 3 target lesions in the liver (segment IV, VI and VII).
- Bevacizumab treatment was initiated during the follow-up study in addition to the concomitant medication patient had at enrollment in the study.
- the patient is a 48-year-old white male randomized for treatment according to the ARFOX protocol (see above).
- the primary rectal tumour is still in place and no adjuvant therapy has been given.
- Genotype testing [2018-11-26] shows patient is KRAS, BRAF and NRAS wildtype.
- Baseline CT+MRI [2018-11-12] showed 3 target lesions; in the liver lobe, in the horronic lymph nodes (lymph nodes) and in left pelvis.
- the patient is a 67-year-old white female randomized for treatment according to the ARFOX protocol (see above). Medical history findings at enrolment are an ostomy surgery in the past and an ongoing Candida infection, but no concomitant medication.
- Genotype testing [2018-12-12] shows patient is KRAS and BRAF wildtype, NRAS mutant.
- Baseline CT [2018-12-16] showed 2 target lesions in the liver (right lobe dorsal lateral).
- 8week CT [2019-02-26] the sum of diameter of the target lesion(s) decreased with 40% (partial response) and patient consented to participation in the follow-up study.
- AEs dry skin grade 1, treated with Canoderm, ileostomy infection grade 2, treated with antibiotics, insomnia grade 1 and loss of appetite grade 2.
- Patient also had a number of AEs related to bone marrow toxicity (neutropenia, leukopenia) with grade ranging from 1-3 - treated accordingly with Zarzio, and a couple of occasions of nausea grade 1 despite a number of prophylactic drugs given.
- neuropathy grade 1 a number of AEs related to bone marrow toxicity (neutropenia, leukopenia) with grade ranging from 1-3 - treated accordingly with Zarzio, and a couple of occasions of nausea grade 1 despite a number of prophylactic drugs given.
- the patient is a 69-year-old white male randomized for treatment according to the ARFOX protocol (see above).
- Genotype testing [2018-12-28] shows patient is KRAS and NRAS wildtype.
- Baseline CT [2018-12-03] showed 3 target lesions; in the part IV of the liver, in left adrenal gland and in lung nodules.
- the patient is a 34-year-old white female randomized for treatment according to the ARFOX protocol (see above).
- Genotype testing [2019-01-31] shows patient is KRAS, BRAF and NRAS wildtype.
- panitimumab was added to the ARFOX treatment during the follow-up study.
- the patient is a 53-year-old white male randomized for treatment according to the ARFOX protocol (see above).
- Medical history finding at enrolment is depression, which is treated with Sobril.
- Other concomitant medication at enrolment is treatment of pain, heartburn, rhinit as well as constipation and thrombosis prophylaxes.
- the primary right sided tumour is still in place and no adjuvant therapy has been given.
- Genotype testing [2019-01-09] shows patient is KRAS wildtype, BRAF mutant, NRAS wildtype and MSS negative.
- Baseline CT [2019-01-02] showed 3 target lesions in the liver (segment IV and VII) and lymph node.
- 8week CT [2019-03-27] the sum of diameter of the target lesion(s) increased with 29% and additional lesions were discovered (progressive disease).
- the patient is a 68-year-old white male randomized for treatment according to the ARFOX protocol (see above).
- Genotype testing [2019-01-31] shows patient is KRAS mutant and MSS negative.
- Baseline CT [2019-02-21] showed 2 target lesions; in segment 6/7 and segment 8 of the liver.
- 8week CT [2019-04-15] the sum of diameter of the target lesion(s) decreased with 53% (partial responses) and patient was thereby eligible for participation in the follow-up study.
- the patient is a 70-year-old white male randomized for treatment according to the ARFOX protocol (see above).
- Genotype testing [2018-09-26] shows patient is MSI stable (microsatellite instability absent).
- Genotype testing [2020-02-04] shows patient is KRAS, BRAF and NRAS wildtype.
- the patient is a 66-year-old white female randomized for treatment according to the ARFOX protocol (see above).
- the primary rectal tumour is still in place and no adjuvant therapy has been given.
- Genotype testing [2019-01-08] shows patient is KRAS mutant and BRAF and NRAS wildtype.
- Baseline CT [2019-03-07] showed 2 target lesions; in the left lower lung lobe and in the right upper lung lobe.
- the patient is a 68-year-old white male randomized for treatment according to the ARFIRI protocol (see above).
- Medical history findings at enrolment are depression, gastroesophageal reflux and insomnia which are treated accordingly. Other medical history findings are untreated atrial fibrillation grade 2 and back pain. Patient also has liver surgery and hemicolectomy reported as medical history.
- the primary left sided tumour has been removed and adjuvant therapy with FOLFOX [EOT 2017-01-05] has been given.
- Genotype testing shows patient is KRAS wildtype, BRAF mutant, NRAS wildtype.
- Baseline MRI [2018-03-06] showed 1 target lesion in the liver (right dorsal).
- the patient had severe problems with Gl related toxicity such as nausea and vomiting.
- Patient was allowed to try the following 5-FU bolus regimen (irinotecan 180 mg/m2 on day 1, bolus 5-FU 500 mg/m2 and arfolitixorin 60 mg/m2 on day 1 and 2) during the followup study without any significant change of toxicity.
- Patient also reported a number of occasions of fatigue grade 1-2 during study participation and initially one episode of paroxysmal atrial fibrillation grade 3 and a month later atrial fibrillation grade 3 - both reported to be related to the study drug by the investigator.
- the patient is a 65-year-old white female randomized for treatment according to the ARFIRI protocol (see above).
- Genotype testing [2018-03-22] shows patient is KRAS, BRAF and NRAS wildtype.
- Baseline CT [2018-03-27] showed 1 target lesion in the pelvis (cervix, near rectal stump).
- the patient is a 74-year-old white male randomized for treatment according to the ARFIRI protocol (see above). Medical history findings at enrolment are hypertension that is treated accordingly, hyperlipidemia and a right hemicolectomy. Patient is treated with Salospir and Placol as cardiovascular prevention.
- the primary right sided tumour has been removed and adjuvant therapy with CAPECITABINE- OXALIPLATIN [EOT 2017-UNK-UNK] has been given.
- Genotype testing [2018-05-04] shows patient is KRAS, BRAF and NRAS wildtype.
- Baseline CT [2018-05-14] showed 5 target lesions in the lung (right and left lobe), abdomen and abdominal aorta.
- the patient is a 67-year-old white male randomized for treatment according to the ARFIRI protocol (see above).
- the primary left sided tumour is still in place and no adjuvant therapy has been given.
- Genotype testing [2018-05-22] shows patient is KRAS mutant, BRAF wildtype and MLH1, PMS2, MSH2 and MSH6 stable.
- Baseline CT [2018-04-16] showed 3 target lesions in the liver; 1 in left lobe apical and 2 in right lobe.
- the patient is a 58-year-old white male randomized for treatment according to the ARFIRI protocol (see above).
- the primary left sided tumour has been removed but no adjuvant therapy has been given.
- Genotype testing [2017-11-28] shows patient is KRAS mutant and BRAF and NRAS wildtype.
- Baseline CT [2018-07-23] showed 2 target lesions in the lung; right lower lobe and lymphnode.
- the patient is a 68-year-old white male randomized for treatment according to the ARFIRI protocol (see above).
- the primary left sided tumour has been removed but no adjuvant therapy has been given.
- Genotype testing [2018-08-10] shows patient is KRAS wildtype, BRAF wildtype and MLH1, PMS2, MSH2 and MSH6 stable.
- Baseline MRI [2018-07-06] showed 2 target lesions in the liver (segment 1 and 7).
- hypotension grade 2 hypotension grade 2
- insomnia grade 1 worsening of restless legs (grade 1) that was reported as medical history.
- the patient is a 58-year-old white female randomized for treatment according to the ARFIRI protocol (see above).
- Medical history findings at enrolment are depression and pain that are treated accordingly.
- Other medical history findings are twisted ovarian cyst, struma [goitre], anorexia, rash, fatigue and dry mouth. Medication for rash is prescribed at enrolment.
- Genotype testing [2018-07-31] shows patient is KRAS mutant and BRAF wildtype, NRAS wildtype.
- Baseline CT [2018-08-22] showed 2 target lesions in retroperitoneal lymph node.
- Dizziness grade 1 and nausea grade 1 are reported at almost every treatment cycle, and nausea is treated with both oral an i.v. nausea prophylaxis.
- Patient also reports several episodes of epistaxis grade 1. Dry skin grade 1 is reported a couple of times and so is pain grade 1, lasting for several weeks at a time. During follow-up study oral mucositis lasting for more than a month is reported, treated with chamomile flower tea.
- the patient is a 65-year-old white male randomized for treatment according to the ARFIRI protocol (see above).
- the primary left sided tumour has been removed but no adjuvant therapy has been given.
- Genotype testing [2017-10-12] shows patient is KRAS mutant and BRAF wildtype.
- Genotype testing [2017-10-13] shows patient is MSI negative.
- Baseline CT [2018-08-23] showed 1 target lesion in segment VI of the liver.
- the patient is a 63-year-old white male randomized for treatment according to the ARFIRI protocol (see above).
- the primary right sided tumour has been removed but no adjuvant therapy has been given. No genotype testing performed.
- Baseline CT [2018-10-29] showed 2 target lesions; left ventral (gland) and left aorta (gland).
- the patient is a 45-year-old white male randomized for treatment according to the ARFIRI protocol (see above).
- the primary right sided tumour has been removed and adjuvant therapy with FLOX [EOT 2017-06-29] has been given.
- Genotype testing [2018-08-06] shows patient is KRAS mutant and MLH1, PMS2, MSH2 and MSH6 stable.
- Baseline CT [2018-12-07] showed 1 target lesion the right lower lobe of the lung, ventral.
- CT the sum of diameter of the target lesion(s) increased with 50% (progressive disease).
- the patient is a 46-year-old Asian female randomized for treatment according to the ARFIRI protocol (see above).
- the primary rectal tumour is still in place and no adjuvant therapy has been given.
- Genotype testing [2018-11-16] shows patient is KRAS and BRAF wildtype and NRAS mutant.
- Baseline CT [2018-12-27] showed 2 target lesions in the liver.
- the patient is a 72-year-old white female randomized for treatment according to the ARFIRI protocol (see above).
- Medical history finding at enrolment is (mild) hypertension treated with hydrochlorothiazide. No other medical history finding nor concomitant medication.
- the primary left sided tumour has been removed but no adjuvant therapy has been given.
- Genotype testing [2019-03-01] shows patient is KRAS and BRAF mutant, NRAS mutant.
- Genotype testing [2019-12-12] shows patient is MSI stable (microsatellite instability absent).
- Baseline CT [2019-03-19] showed 1 target lesion in the lung (left upper lobe).
- the patient is a 68-year-old white female randomized for treatment according to the ARFIRI protocol (see above).
- the primary left sided tumour has been removed but no adjuvant therapy has been given.
- Genotype testing [2019-04-11] shows patient is BRAF mutant and MSI stable (microsatellite instability absent).
- Genotype testing [2019-04-16] shows patient is KRAS wildtype.
- Genotype testing [2019-04-19] shows patient is NRAS wildtype.
- Baseline CT [2019-04-03] showed 3 target lesions in the liver (right lobe) and lung (right lobe).
- 8week CT [2019-06-04] the sum of diameter of the target lesion(s) decreased with 54% (partial response) and patient consented to participation in the follow-up study.
- the patient is a 52-year-old white female randomized for treatment according to the ARFIRI protocol (see above).
- Genotype testing [2019-04-25] shows patient is KRAS and BRAF mutant, NRAS wildtype.
- Genotype testing [2019-04-19] shows patient is MSI stable (microsatellite instability absent).
- Baseline CT [2019-03-13] showed 2 target lesions in the lung (left and right lower lobe).
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne le traitement du cancer colorectal chez les populations humaines ayant une haute fréquence de mutations de BRAF- ou KRAS-, qui consiste à administrer de multiples bolus de [6R]-5,10-méthylènetétrahydrofolate ([6R]-MTHF) en liaison avec la chimiothérapie à base de 5-fluorouracile (5-FU).
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2021/076512 WO2023046304A1 (fr) | 2021-09-27 | 2021-09-27 | [6r]-mthf dans une chimiothérapie à base de 5-fu de cancer colorectal à mutation de kras ou braf |
PCT/EP2022/076606 WO2023046940A1 (fr) | 2021-09-27 | 2022-09-26 | [6r]-mthf utilisé dans la chimiothérapie basée sur 5-fu du cancer colorectal à mutation braf ou kras |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2021/076512 WO2023046304A1 (fr) | 2021-09-27 | 2021-09-27 | [6r]-mthf dans une chimiothérapie à base de 5-fu de cancer colorectal à mutation de kras ou braf |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023046304A1 true WO2023046304A1 (fr) | 2023-03-30 |
Family
ID=78086334
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2021/076512 WO2023046304A1 (fr) | 2021-09-27 | 2021-09-27 | [6r]-mthf dans une chimiothérapie à base de 5-fu de cancer colorectal à mutation de kras ou braf |
PCT/EP2022/076606 WO2023046940A1 (fr) | 2021-09-27 | 2022-09-26 | [6r]-mthf utilisé dans la chimiothérapie basée sur 5-fu du cancer colorectal à mutation braf ou kras |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/076606 WO2023046940A1 (fr) | 2021-09-27 | 2022-09-26 | [6r]-mthf utilisé dans la chimiothérapie basée sur 5-fu du cancer colorectal à mutation braf ou kras |
Country Status (1)
Country | Link |
---|---|
WO (2) | WO2023046304A1 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018150264A1 (fr) * | 2017-02-14 | 2018-08-23 | Isofol Medical Ab | Méthodes permettant d'augmenter la 2'-déoxyuridine (durd) du plasma sanguin et inhibition de la thymidylate synthase |
EP3446703A1 (fr) * | 2017-08-24 | 2019-02-27 | Isofol Medical AB | Administration de bolus multiples 6r]-mthf dans une chimiothérapie à base de 5-fluorouracile |
WO2019135157A1 (fr) * | 2018-01-05 | 2019-07-11 | Isofol Medical Ab | Méthodes pour traiter un cancer colorectal et des cancers colorectaux métastatiques |
-
2021
- 2021-09-27 WO PCT/EP2021/076512 patent/WO2023046304A1/fr unknown
-
2022
- 2022-09-26 WO PCT/EP2022/076606 patent/WO2023046940A1/fr unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018150264A1 (fr) * | 2017-02-14 | 2018-08-23 | Isofol Medical Ab | Méthodes permettant d'augmenter la 2'-déoxyuridine (durd) du plasma sanguin et inhibition de la thymidylate synthase |
EP3446703A1 (fr) * | 2017-08-24 | 2019-02-27 | Isofol Medical AB | Administration de bolus multiples 6r]-mthf dans une chimiothérapie à base de 5-fluorouracile |
WO2019037899A1 (fr) | 2017-08-24 | 2019-02-28 | Isofol Medical Ab | Administration de multiples bolus de [6r]-mthf au cours d'une chimiothérapie à base de 5-fluoro-uracile |
WO2019135157A1 (fr) * | 2018-01-05 | 2019-07-11 | Isofol Medical Ab | Méthodes pour traiter un cancer colorectal et des cancers colorectaux métastatiques |
Non-Patent Citations (42)
Also Published As
Publication number | Publication date |
---|---|
WO2023046940A1 (fr) | 2023-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Seront et al. | Phase II study of dual phosphoinositol‐3‐kinase (PI 3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ 235 in patients with locally advanced or metastatic transitional cell carcinoma | |
IL256326B1 (en) | Biomarkers for nanoparticle preparations | |
Van Cutsem et al. | A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients | |
JP6805336B2 (ja) | 薬学的組み合わせ | |
JP2022051965A (ja) | がんの処置 | |
CA3108236A1 (fr) | Methodes et compositions pour l'inhibition de la voie egf/egfr en combinaison avec des inhibiteurs de kinase de lymphome anaplasique | |
JP2013537544A (ja) | 抗癌剤併用療法 | |
Bennouna et al. | A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer | |
JP6410795B2 (ja) | カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物 | |
US20230095428A1 (en) | [6r]-mthf in 5-fu based chemotherapy of braf- or kras-mutated colorectal cancer | |
US20230097085A1 (en) | [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer | |
WO2023046304A1 (fr) | [6r]-mthf dans une chimiothérapie à base de 5-fu de cancer colorectal à mutation de kras ou braf | |
US20230102483A1 (en) | [6r]-mthf in 5-fu based chemotherapy of left-sided colorectal cancer | |
WO2023046307A1 (fr) | [6r]-mthf dans une chimiothérapie à base de 5-fu du cancer colorectal côté droit | |
JP2024519060A (ja) | ソトラシブ投与レジメン | |
TW202200147A (zh) | Belvarafenib用於癌症治療 | |
JP7303205B2 (ja) | 胆道癌を処置するための方法および併用療法 | |
Jones et al. | A Randomized Phase II Trial of Oral Topotecan Versus Docetaxel in the Second-Line Treatment of Non–Small-Cell Lung Cancer | |
US20240101656A1 (en) | Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer | |
WO2018065445A1 (fr) | Administration de multiples bolus de [6r]-mthf au cours d'une chimiothérapie à base de 5-fluoro-uracile | |
WO2018065446A1 (fr) | [6r]-mthf - alternative efficace du folate dans la chimiothérapie à base de 5-fluorouracile | |
RU2793543C2 (ru) | Способы и комбинированное терапевтическое средство для лечения рака желчных протоков | |
Macedo et al. | Therapeutic impact of determination of RAS mutations in the plasma of patients with colorectal cancer: Impact of RAS mutations in colorectal cancer | |
KR20230165795A (ko) | 벨바라페닙 및 코비메티닙 또는 벨바라페닙, 코비메티닙 및 아테졸리주맙을 이용한 병용 요법 | |
TW202317123A (zh) | Erk1/2及cdk4/6抑制劑之組合療法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21790092 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |